amyloid aggregation inhibitors (Pfizer/Yamanouchi)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameamyloid aggregation inhibitors (Pfizer/Yamanouchi)
Drug Alias NameAlzheimers disease therapeutic (Pfizer/Yamanouchi)amyloid aggregation inhibitors (Pfizer/Astellas)PD-0118057PD-0317791PD-0202091
ClassificationSmall molecules
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncYamanouchi Pharmaceutical Co LtdAstellas Pharma Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A